+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Primary Biliary Cirrhosis - Pipeline Review, H1 2019

  • ID: 4750061
  • Drug Pipelines
  • 128 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Arena Pharmaceuticals Inc
  • Cadila Healthcare Ltd
  • Dr. Falk Pharma GmbH
  • Genfit SA
  • Gilead Sciences Inc
  • MORE
Primary Biliary Cirrhosis - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2019, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

This latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 11, 3, 1, 2 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Arena Pharmaceuticals Inc
  • Cadila Healthcare Ltd
  • Dr. Falk Pharma GmbH
  • Genfit SA
  • Gilead Sciences Inc
  • MORE
Introduction

Primary Biliary Cirrhosis - Overview

Primary Biliary Cirrhosis - Therapeutics Development

Primary Biliary Cirrhosis - Therapeutics Assessment

Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development

Primary Biliary Cirrhosis - Drug Profiles

Primary Biliary Cirrhosis - Dormant Projects

Primary Biliary Cirrhosis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Primary Biliary Cirrhosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2019

Primary Biliary Cirrhosis - Pipeline by Allergan Plc, H1 2019

Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2019

Primary Biliary Cirrhosis - Pipeline by Biocad, H1 2019

Primary Biliary Cirrhosis - Pipeline by Cadila Healthcare Ltd, H1 2019

Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2019

Primary Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H1 2019

Primary Biliary Cirrhosis - Pipeline by Eli Lilly and Co, H1 2019

Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2019

Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2019

Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2019

Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2019

Primary Biliary Cirrhosis - Pipeline by Kowa Co Ltd, H1 2019

Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2019

Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2019

Primary Biliary Cirrhosis - Pipeline by Tiziana Life Sciences Plc, H1 2019

Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2019

Primary Biliary Cirrhosis - Dormant Projects, H1 2019

List of Figures

Number of Products under Development for Primary Biliary Cirrhosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Albireo Pharma Inc
  • Allergan Plc
  • Arena Pharmaceuticals Inc
  • Biocad
  • Cadila Healthcare Ltd
  • CymaBay Therapeutics Inc
  • Dr. Falk Pharma GmbH
  • Eli Lilly and Co
  • Enanta Pharmaceuticals Inc
  • Genfit SA
  • GenKyoTex SA
  • Gilead Sciences Inc
  • Kowa Co Ltd
  • NGM Biopharmaceuticals Inc
  • Novartis AG
  • Tiziana Life Sciences Plc
  • Virobay Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4750061
Adroll
adroll